Without the On-CARlytics patient protection, the product would not be seen as a valuable asset.
I see this as Imugene Management showing some confidence moving forward.
With the amount of time, resource and funds that go into obtaining a patient is an immense project within itself.
If anybody on the forum has tried & succeeded in obtaining a patient, you will know what i mean.
It's just not worth the expense unless you have some confidence with what you're looking to achieve.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $179.4K | 14.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 15731879 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3463196 | 20 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |